Maxim Group reissued their buy rating on shares of Biopharmx (NYSEAMERICAN:BPMX) in a research note released on Friday. The firm currently has a $1.50 price target on the biotechnology company’s stock.

“BPMX reported mixed F3Q18 (Oct) results. Revenue of $18,000, down 45.5% y/y, was above our estimate of $9,100, but below consensus of $20,000. GAAP EPS of ($0.05), compared to ($0.12) in F3Q17, was narrower than our estimate of ($0.06) and inline with consensus of ($0.05). The company also received positive feedback from the FDA on the design of its planned phase 3 clinical trial of BPX-01 for acne. As of October 31, 2017, cash and cash equivalents were $1.6M. On November 24, 2017, BPMX completed an $11M public offering that is expected to fund a phase 2 rosacea trial.”,” the firm’s analyst wrote.

Separately, HC Wainwright reaffirmed a buy rating and set a $3.00 price objective on shares of Biopharmx in a research report on Tuesday, September 19th.

Shares of Biopharmx (NYSEAMERICAN:BPMX) opened at $0.11 on Friday. Biopharmx has a 52 week low of $0.11 and a 52 week high of $0.90.

Biopharmx (NYSEAMERICAN:BPMX) last released its earnings results on Wednesday, September 13th. The biotechnology company reported ($0.06) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.06). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. Biopharmx had a negative return on equity of 5,749.08% and a negative net margin of 22,005.88%.

In other news, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of the business’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $0.20, for a total value of $59,278.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Stephen Morlock acquired 330,000 shares of the business’s stock in a transaction dated Friday, November 24th. The stock was acquired at an average price of $0.15 per share, with a total value of $49,500.00. The disclosure for this purchase can be found here.

TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/maxim-group-reiterates-buy-rating-for-biopharmx-bpmx/1758608.html.

About Biopharmx

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.